Data support addition of AI to iCAD’s DBT
NASHUA, N.H. & ATHENS, Greece—October saw medical technology provider iCAD Inc. share clinical results for its new digital breast tomosynthesis (DBT) cancer detection software. The data showed that adding the latest artificial intelligence (AI) software solution to support DBT led to improvements in reader sensitivity and specificity by an average of 8.0 and 6.9 percent, respectively. When reading tomosynthesis cases with this solution, reading times decreased by 52.7 percent on average. iCAD’s solution detects malignancies and estimates the probability of malignant findings, providing scores that represent the algorithm’s certainty that detected tissue densities and calcifications are malignant.
“As tomosynthesis moves into the screening arena, our AI software provides important benefits to radiologists, their practices and their patients,” said Dr. Jeff Hoffmeister, vice president and medical director at iCAD.